Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2057857 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2HIF1AMAPT | |
| SCHEMBL2057744 | 0.76 | EGLN1 (0.44) | EGLN1HIF1A | |
| SCHEMBL2057951 | 0.74 | NPC1 (0.43) | EGLN1SMN1; SMN2THRBEGLN3 | |
| SCHEMBL2057846 | 0.69 | EGLN1 (0.43) | EGLN1HIF1A | |
| SCHEMBL1920729 | 0.68 | SMN1; SMN2 (0.46) | SMN1; SMN2HIF1ATP53THRBMAPT | |
| SCHEMBL4056990 | 0.67 | EGLN1 (0.47) | EGLN1EGLN3 | |
| SCHEMBL337679 | 0.66 | EGLN1 (0.52) | EGLN1HIF1A | |
| SCHEMBL2057284 | 0.65 | KDM4E (0.47) | EGLN1EGLN3 | |
| SCHEMBL2582539 | 0.65 | EGLN1 (0.56) | EGLN1HIF1A | |
| SCHEMBL3961179 | 0.65 | EGFR (0.49) | EGLN1HIF1AEGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160227-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2011-06-30 | — | — | US | claimed |
| US-20110160227-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110160227-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110160227-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2011-06-30 | — | — | US | disclosed |
| WO-2010022307-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160227-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | EGLN1 6/4885SMN1; SMN2 3690/4885HIF1A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.